本文關(guān)鍵詞： 宮頸腫瘤 肺轉(zhuǎn)移 治療 預(yù)后　出處：《腫瘤學(xué)雜志》2016年12期 　論文類型：期刊論文

【摘要】：[目的]探討宮頸癌治療后肺轉(zhuǎn)移的臨床特點(diǎn),評(píng)價(jià)紫杉醇聯(lián)合卡鉑或順鉑(TC/TP方案)對(duì)宮頸癌治療后肺轉(zhuǎn)移的療效和安全性,并分析預(yù)后影響因素。[方法]收集28例接受TC/TP方案化療的宮頸癌治療后肺轉(zhuǎn)移患者的臨床資料,分析其臨床特點(diǎn),觀察TC/TP方案的有效率、疾病控制率及患者的不良反應(yīng),并探討預(yù)后影響因素。[結(jié)果]28例患者中有16例為早期(Ⅰb~Ⅱa期)術(shù)后患者;12例為Ⅱb~Ⅲb期患者。28例患者肺轉(zhuǎn)移發(fā)生時(shí)間在原發(fā)疾病治療1~5年內(nèi)。肺轉(zhuǎn)移發(fā)生后TC/TP方案有效率(CR+PR)為46.4%,疾病控制率(CR+PR+SD)為60.7%,中位生存時(shí)間18個(gè)月,5年生存率10.7%,Ⅲ~Ⅳ級(jí)胃腸道反應(yīng)、骨髓抑制及腎毒性發(fā)生率分別為5.0%、15.0%、0;單因素分析影響肺轉(zhuǎn)移患者的預(yù)后因素,結(jié)果顯示宮頸癌的病理類型、分化程度、原發(fā)腫瘤大小、肺轉(zhuǎn)移灶的大小與宮頸癌肺轉(zhuǎn)移患者的生存率有關(guān)(P0.05),多因素分析顯示,僅宮頸癌的分化程度是宮頸癌肺轉(zhuǎn)移患者預(yù)后的獨(dú)立影響因素。[結(jié)論]要重視宮頸癌治療后發(fā)生肺轉(zhuǎn)移的問(wèn)題;TC/TP方案對(duì)宮頸癌治療后肺轉(zhuǎn)移患者有效且不良反應(yīng)能耐受;對(duì)于這些患者中的低分化者應(yīng)加強(qiáng)治療方法的研究及監(jiān)測(cè)。
[Abstract]:[objective] to investigate the clinical features of lung metastasis after treatment of cervical cancer, and to evaluate the efficacy and safety of paclitaxel combined with carboplatin or cisplatin TC- / TP regimen in the treatment of cervical cancer. [methods] the clinical data of 28 patients with lung metastasis after chemotherapy with TC/TP regimen were collected and their clinical characteristics were analyzed. The effective rate, disease control rate and adverse reactions of patients with TC/TP regimen were observed. [results] among 28 patients, 16 were early (stage 鈪，

本文編號(hào)：1510488